Want to know what's happening next in healthcare?

MedCityNews is the leading online news source for the business of innovation in healthcare.

“Follow MedCity News if you want to know who is doing what in healthcare innovation - and whether it's working or not.”

Chris Seper, CEO & Founder, MedCityNews.com

Sign up for our daily newsletter

Ablynx gets good results for inhaled drug for RSV in infants

3:55 am by | 0 Comments

BRUSSELS (Reuters) - Belgian drug developer Ablynx has successfully completed early-stage tests on healthy volunteers for its inhaled treatment for RSV, a virus which is the most common cause of bronchiolitis in babies.

Ablynx said on Tuesday the phase I tests showed ALX-0171 was the first antibody that can be administered directly into the lung using a nebuliser inhalation device, as it uses the group's proprietary ultra-small nanobody technology, derived from llamas.

The result pushed Ablynx shares up as much as 5 percent to a high of 3.95 euros, to make the company the sharpest climber in Brussels.

"This is the first clinical confirmation of a key differentiating characteristic of the platform," KBC said in a note to clients as it increased its recommendation to "Buy" from "Accumulate" and raised its price target to 7 euros from 6 euros.


Ablynx was due to release Phase II results for its rheumatoid arthritis drug, ALX-0061, next month.

([email protected]; +32 2287 6811; Reuters Messaging: rm://[email protected])

Copyright 2014 MedCity News. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
Sort: Newest | Oldest